Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model

A. D. Kulkarni, P. R. Van Ginkel, S. R. Darjatmoko, M. J. Lindstrom, Daniel Albert

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Retinoblastoma is the most common primary malignant intraocular neoplasm of childhood. The poor outcomes of patients with metastatic retinoblastoma have encouraged the search for new therapies. In the current study, the efficacy of combination therapy with calcitriol and cisplatin in athymic mice with subcutaneous Y-79 human retinoblastoma tumours was assessed. Methods: 60 athymic mice were subcutaneously injected with human Y79 retinoblastoma cells. Animals were randomised into four groups: group 1, 50 μg of cisplatin; group 2, 0.05 μg of calcitriol; group 3, 0.05 μg of calcitriol and 50 μg of cisplatin; group 4, control. The cisplatin was administered once a week, and the calcitriol was given five times a week. Results: There was a significant inhibition of tumour growth in animals treated with the combination therapy of calcitriol and cisplatin as compared with controls and cisplatin alone (p=0.0001 and p=0.0041 respectively). In terms of toxicity, serum calcium levels were increased, but there was no mortality and minimal nephrotoxicity in any of the groups. Conclusion: The present study shows that cisplatin given in combination with calcitriol may be a viable multidrug therapy option in the treatment of high-risk retinoblastoma.

Original languageEnglish (US)
Pages (from-to)1105-1108
Number of pages4
JournalBritish Journal of Ophthalmology
Volume93
Issue number8
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Retinoblastoma
Calcitriol
Heterografts
Cisplatin
Nude Mice
Therapeutics
Neoplasms
Calcium
Control Groups
Mortality
Growth
Serum

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. / Kulkarni, A. D.; Van Ginkel, P. R.; Darjatmoko, S. R.; Lindstrom, M. J.; Albert, Daniel.

In: British Journal of Ophthalmology, Vol. 93, No. 8, 01.08.2009, p. 1105-1108.

Research output: Contribution to journalArticle

Kulkarni, A. D. ; Van Ginkel, P. R. ; Darjatmoko, S. R. ; Lindstrom, M. J. ; Albert, Daniel. / Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. In: British Journal of Ophthalmology. 2009 ; Vol. 93, No. 8. pp. 1105-1108.
@article{bda64becfb664761b7ffdc8a1c57bc95,
title = "Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model",
abstract = "Background: Retinoblastoma is the most common primary malignant intraocular neoplasm of childhood. The poor outcomes of patients with metastatic retinoblastoma have encouraged the search for new therapies. In the current study, the efficacy of combination therapy with calcitriol and cisplatin in athymic mice with subcutaneous Y-79 human retinoblastoma tumours was assessed. Methods: 60 athymic mice were subcutaneously injected with human Y79 retinoblastoma cells. Animals were randomised into four groups: group 1, 50 μg of cisplatin; group 2, 0.05 μg of calcitriol; group 3, 0.05 μg of calcitriol and 50 μg of cisplatin; group 4, control. The cisplatin was administered once a week, and the calcitriol was given five times a week. Results: There was a significant inhibition of tumour growth in animals treated with the combination therapy of calcitriol and cisplatin as compared with controls and cisplatin alone (p=0.0001 and p=0.0041 respectively). In terms of toxicity, serum calcium levels were increased, but there was no mortality and minimal nephrotoxicity in any of the groups. Conclusion: The present study shows that cisplatin given in combination with calcitriol may be a viable multidrug therapy option in the treatment of high-risk retinoblastoma.",
author = "Kulkarni, {A. D.} and {Van Ginkel}, {P. R.} and Darjatmoko, {S. R.} and Lindstrom, {M. J.} and Daniel Albert",
year = "2009",
month = "8",
day = "1",
doi = "10.1136/bjo.2008.152843",
language = "English (US)",
volume = "93",
pages = "1105--1108",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model

AU - Kulkarni, A. D.

AU - Van Ginkel, P. R.

AU - Darjatmoko, S. R.

AU - Lindstrom, M. J.

AU - Albert, Daniel

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Retinoblastoma is the most common primary malignant intraocular neoplasm of childhood. The poor outcomes of patients with metastatic retinoblastoma have encouraged the search for new therapies. In the current study, the efficacy of combination therapy with calcitriol and cisplatin in athymic mice with subcutaneous Y-79 human retinoblastoma tumours was assessed. Methods: 60 athymic mice were subcutaneously injected with human Y79 retinoblastoma cells. Animals were randomised into four groups: group 1, 50 μg of cisplatin; group 2, 0.05 μg of calcitriol; group 3, 0.05 μg of calcitriol and 50 μg of cisplatin; group 4, control. The cisplatin was administered once a week, and the calcitriol was given five times a week. Results: There was a significant inhibition of tumour growth in animals treated with the combination therapy of calcitriol and cisplatin as compared with controls and cisplatin alone (p=0.0001 and p=0.0041 respectively). In terms of toxicity, serum calcium levels were increased, but there was no mortality and minimal nephrotoxicity in any of the groups. Conclusion: The present study shows that cisplatin given in combination with calcitriol may be a viable multidrug therapy option in the treatment of high-risk retinoblastoma.

AB - Background: Retinoblastoma is the most common primary malignant intraocular neoplasm of childhood. The poor outcomes of patients with metastatic retinoblastoma have encouraged the search for new therapies. In the current study, the efficacy of combination therapy with calcitriol and cisplatin in athymic mice with subcutaneous Y-79 human retinoblastoma tumours was assessed. Methods: 60 athymic mice were subcutaneously injected with human Y79 retinoblastoma cells. Animals were randomised into four groups: group 1, 50 μg of cisplatin; group 2, 0.05 μg of calcitriol; group 3, 0.05 μg of calcitriol and 50 μg of cisplatin; group 4, control. The cisplatin was administered once a week, and the calcitriol was given five times a week. Results: There was a significant inhibition of tumour growth in animals treated with the combination therapy of calcitriol and cisplatin as compared with controls and cisplatin alone (p=0.0001 and p=0.0041 respectively). In terms of toxicity, serum calcium levels were increased, but there was no mortality and minimal nephrotoxicity in any of the groups. Conclusion: The present study shows that cisplatin given in combination with calcitriol may be a viable multidrug therapy option in the treatment of high-risk retinoblastoma.

UR - http://www.scopus.com/inward/record.url?scp=68049092791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049092791&partnerID=8YFLogxK

U2 - 10.1136/bjo.2008.152843

DO - 10.1136/bjo.2008.152843

M3 - Article

VL - 93

SP - 1105

EP - 1108

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 8

ER -